Another study showed that idelalisib induced a downregulation of CD62L in vivo in CLL patients, which is most likely associated with an increase in the rolling velocity and the subsequent impaired adhesion of CLL cells onto the HEV [125]. The gene discussed is SELL; the disease is B-cell chronic lymphocytic leukemia.